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A report on a Joint Cold Spring Harbor Laboratory/
Wellcome Trust Conference on ‘Prion Biology’, Hinxton,
UK, 7-11 September 2005.
While most recent prion meetings have focused on either
mammals or fungi, the conference on prion biology held
near Cambridge this September stood out as an attempt to
represent research on mammalian and fungal prions
equally, in order to provoke discussion on fundamental
questions of prion structure, biogenesis, variability and
biological role. 
Prions of lower eukaryotes
Over the past decade several infective proteins, or prions,
have been discovered in genetically tractable lower eukaryotes,
where they act like cytoplasmically inherited genetic deter-
minants. The opening talk of the meeting was delivered by
Reed Wickner (National Institutes of Health, Bethesda,
USA), who was the first to suggest 11 years ago that the non-
chromosomal genetic determinants known as [URE3] and
[PSI+] in the yeast Saccharomyces cerevisiae were in fact
prion proteins (enclosure in square brackets is the conven-
tional nomenclature for cytoplasmically inherited genetic
determinants in fungi). The proteins that correspond to
[URE3] and [PSI+], regulator of nitrogen metabolism Ure2
and translation termination factor Sup35, respectively, have
carboxy-terminal domains that carry out a cellular function
and auxiliary amino-terminal prion domains, which can
adopt an abnormal ‘prion’ conformation. The prion domains
of both these proteins are rich in glutamine (Q) and
asparagine (N), but only that of Sup35 contains oligopeptide
repeats, which are presumably required for [PSI+] replication.
Previously, Wickner’s group had shown that random shuffling
of amino acids in the Ure2 prion domain, a procedure
named scrambling, usually does not impair the prion-
forming capacity of the protein. At this meeting, Wickner
described how randomization of the Sup35 prion domain,
including the repeat region, also does not block prion forma-
tion, and concluded that unusual amino-acid composition,
rather than specific sequences, determines prion-forming
ability. According to Wickner, these experiments argue for
an in-register parallel β-sheet structure for the prion fibrils,
as scrambling would disrupt the correspondence of amino
acids in any other -strand structure.
Susan Lindquist (Whitehead Institute, Cambridge, USA)
described elegant Sup35 cross-linking experiments that
revealed that Sup35 monomers in amyloid fibrils are
arranged in a ‘head-to-head, tail-to-tail’ fashion. Amyloid is
the general name given to the fibrillar protein aggregate
formed by prions and some other proteins. Such amyloid
structure also implies parallel in-register arrangement of
β strands in the prion fibrils. Lindquist proposed that these
considerations, combined with the β-helical nanotube struc-
ture of the Sup35 fibrils, suggested a new structural model
for prions, which may have broad implications for amyloids. 
Prions come in different variants or ‘strains’. In mammals,
whose prions are infectious agents causing a set of fatal
neurodegenerative diseases, different prion strains are
defined by specific incubation times, distribution of vacuolar
lesions in the brain, and patterns of accumulation. For yeast
[PSI+], strain differences can be revealed by differences in
phenotypic manifestation (nonsense suppression caused by
the aggregation-dependent inactivation of the translation
termination factor Sup35) and stability of maintenance.Generally, ‘weak’ [PSI+] manifest less stable inheritance and
worse phenotypic manifestation than ‘strong’ [PSI+]. From
her results, Lindquist suggested a structural basis for [PSI+]
variants: in ‘weak’ [PSI+] variants a longer Sup35 fragment is
incorporated into the amyloid core. The physical basis of
prion strain differences was also considered by Jonathan
Weissman (University of California, San Francisco, USA). His
group had previously shown that Sup35 fibrils obtained in
vitro at 4°C and 37°C transform yeast cells to strong [PSI+]
variants, and weak [PSI+], respectively. Atomic force
microscopy revealed two distinctions between the 4°C (Sc4)
and 37°C (Sc37) fibrils. Sc4 fibrils polymerized more slowly
than Sc37, but were more fragile and therefore smaller
and more numerous, which ensured their efficient polymeriza-
tion. Correlated with the strong phenotype of Sc4 fibrils is
the fact that they are more susceptible to fragmentation in
vivo than Sc37, presumably as the result of the activity of
chaperone proteins. Thus, the efficiency of fibril severing
by chaperones correlates with the mechanical strength of
the fibril. 
The search for novel prion proteins goes on, as their discovery
might enable new prion-related processes in nature to be
uncovered and the importance of prions to be estimated.
Pascale Beauregard (Université de Montreal, Canada)
reported convincing genetic and biochemical data for the
existence of a prion in Schizosaccharomyces pombe, the first
to be found in a yeast other than S. cerevisiae. This prion,
[cif1], allows cell survival in the absence of the essential chap-
erone, calnexin. Jessica Brown (Massachusetts Institute of
Technology, Cambridge, USA) described in her poster a novel
prion-like determinant of S. cerevisiae, named [GAR+],
which determines resistance to the non-hydrolyzable glucose
analog D-(+)-glucosamine. In contrast to known yeast prions,
[GAR+] is not cured by deletion of the heat-shock protein
gene HSP104, but is cured by simultaneous deletion of the
SSA1 and SSA2 genes encoding Hsp70 heat-shock proteins.
Ludmila Mironova (St Petersburg University, Russia)
described a search for proteins underlying [ISP+], another
Hsp104-independent prion-like determinant causing anti-
suppression, a phenotype opposite to that of [PSI+]. A likely
candidate for the [ISP+] prion protein is the transcriptional
factor Sfp1. One of us (I.D.) presented biochemical and
microscopic evidence for the prion nature of the Lsm4
protein, one of several candidate prions which were identified
previously in a genetic screen for the [PIN+] protein. 
Although relatively few investigators study the [Het-s] prion
of the filamentous fungus Podospora anserina, their results
make a significant contribution to the prion field. Indeed,
[Het-s] is the only prion with a confirmed biological function:
fusion of a [Het-s] mycelium with one expressing the non-
prionizable het-S allele triggers the heterokaryon incom-
patibility reaction, which leads to the death of the hybrid
mycelium. Recent progress in understanding the molecular
basis of this incompatibility reaction was reported by Sven
Saupe (Institute de Biochemie et de Génétique Cellulaire,
Bordeaux, France), who has shown that the carboxy-terminal
domain of HET-S is prionizable, but prion formation is
blocked by the functional amino-terminal domain. Presum-
ably, HET-S can co-polymerize with the HET-s protein, and
their oligomers trigger the incompatibility reaction. Ronald
Riek (The Salk Institute, La Jolla, USA), Cristiane Ritter
(The Salk Institute) and Ansgar Siemer (ETH Zurich,
Switzerland) consecutively presented their excellent collabo-
rative structural studies of [Het-s], which have particularly
broad significance. The normally flexible carboxy-terminal
tail of the HET-s protein can undergo a spontaneous con-
formational transition into amyloid fibrils. The fold of these
fibrils comprises four β strands made up of two pseudo-repeat
sequences, each forming a β-strand-turn-β-strand motif.
Structure-based mutagenesis revealed that this conformation
is the functional and infectious entity of the HET-s prion.
Several speakers focused on the mechanisms underlying the
de novo appearance of yeast prions. It is known that the
prion form of the Rnq1 protein, [PIN+], promotes the de
novo appearance of [PSI+] and [URE3], apparently by
directly seeding QN-rich prion aggregates. Susan Liebman
(University of Illinois, Chicago, USA) presented further
studies on the interaction between [PIN+], [PSI+] and an
artificial prion, [CHI+]. [PIN+] efficiently seeded [CHI+],
while [PSI+] stimulated the appearance of [PIN+]. While it
appears overall that all QN-rich prions can stimulate each
other’s appearance, evidence suggesting that similar interac-
tions may occur with non-QN-rich prions was also presented.
Mick Tuite and colleagues (University of Kent, Canterbury,
UK) have studied the appearance of [PSI+] at natural Sup35
levels. The appearances of [PSI+] were not related to any
alterations in the gene SUP35, and they were not affected by
chemical agents that cause protein misfolding. The study of
proteins associated with Sup35 revealed the presence in
[PIN+] [psi-] cells ([psi-] denotes the absence of [PSI+]) of a
small oligomeric complex insoluble in the detergent SDS,
and containing both Sup35 and Rnq1 proteins. This finding
is important because hybrid particles may represent an
intermediate step leading to the appearance of [PSI+].
The biological importance of prions was discussed by Kim
Allen (Columbia University, New York, USA). Earlier studies
suggested that the prion-like behavior of the translational
regulator protein CPEB may underlie memory formation in
the mollusc Aplysia. Allen showed that several mouse CPEB
homologs also form prion-like aggregates in yeast, and that
aggregate size, number and distribution are affected by the
expression of chaperones. Aggregate formation by mouse
full-length CPEB-3 and CPEB-4 proteins was also shown in
neuroblastoma cells. The amino-terminal domain of mouse
CPEB-3 is rich in glutamine, similar to yeast prions, whereas
the amino-terminal domain of CPEB-4 is rich in proline and
harbors sequence motifs similar to those implicated in
amyloid formation by the mammalian prion protein PrP.
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nature of memory in higher eukaryotes, it represents a
significant step towards this. 
Mammalian prions
Claudio Soto (University of Texas, Galveston, USA) presented
impressive results on in vitro amplification of PrPSc, the
infectious form of PrP, in the protein misfolding cyclic
amplification system (PMCA). He demonstrated that PMCA
is capable of amplifying prion infectivity with indefinite dilu-
tions of minuscule amounts of initial PrPSc seeds. Soto
emphasized the potential application of PMCA for detection
of ultra-low levels of infectivity in blood. Surachai Supattapone
(Dartmouth Medical School, Hanover, USA) presented the
results of experiments in which PMCA was used to generate
the protease-resistant conformer of the prion protein using
PrPSc purified from scrapie brains and PrPC (the normal
conformer of PrP) purified from normal brains. Ongoing
bioassay experiments with these in vitro-generated PrPSc
produced in the presence of additional synthetic cofactors
may eventually reveal all the molecular components
required for the efficient replication of prions. While ampli-
fication of PrPSc using components extracted from normal
and scrapie brains seems completely successful, reconstitu-
tion of prion infectivity de novo from synthetic components
still remains puzzling.
In his presentation, Bruce Chesebro (Rocky Mountain Labo-
ratories, Hamilton, USA) clearly demonstrated that prion
toxicity could be separated from prion infectivity. He showed
that the onset of typical clinical scrapie was substantially
delayed in mice that expressed PrP without a glycosylphos-
phatidylinositol anchor. Remarkably, these mice were able
to replicate prion infectivity and produced the protease-
resistant conformer of PrP in the form of amyloid plaques,
but failed to develop clinical symptoms of prion disease for a
prolonged time. Byron Caughey (Rocky Mountain Laborato-
ries, Hamilton, USA), on the other hand, took a biochemical
approach to identifying the most infectious prion particles.
Fractionation of PrP by size revealed that the highest level
of infectivity per unit of mass belongs to particles with
approximate molecular weights of only 300-600 kDa. A
question of great interest is whether these highly infectious
prion particles originate from fibril fragmentation or from
distinct non-fibrillar species. 
Neil Mabbott (Institute for Animal Health, Edinburgh, UK)
discussed routes of prion migration between potential sites of
exposure and the lymphoid tissues. He emphasized the possi-
bility of acquiring infectious prions through the skin and the
role of Langerhans cells (dendritic cells) in transporting
prions to the lymphoid tissues. Adriano Aguzzi (University
Hospital, Zurich, Switzerland) presented results that suggest
a relatively high likelihood of prion transmission through
urine, which could be one of the possible means of horizontal
spread of prions in brain-wasting disease of elk and deer.
Roger Morris (Wolfson Centre for Age-Related Disease,
King’s College London, London, UK) described his work on
identifying the neuronal transmembrane receptor that is
involved in the rapid recycling of PrPC and the cellular uptake
of PrPSc. He found that PrPSc bound to the surface of primary
neurons was rapidly endocytosed. Internalization of PrPSc
was in direct competition with internalization of PrPC,
implying that the same receptor was involved in both
processes. 
Edward Malaga-Trillo (University of Konstanz, Germany)
presented a new evolutionary perspective on the possible
function of PrP and the molecular mechanisms driving the
diversification of PrP domains from fish to mammals. He
reported the establishment of a novel genetic model for prion
research, the zebrafish. Most notably, using the zebrafish
model, Malaga-Trillo presented the first clear PrP loss-of-
function phenotypes, which might be used to delineate a con-
served function of vertebrate PrPs during early development. 
In the closing lecture, Christopher Dobson (University of
Cambridge, UK) considered general questions of amyloid
formation. He presented evidence in support of the concept
that the ability of proteins to form amyloid is generic. Many
normally non-amyloidogenic proteins can form amyloid in
vitro under conditions that destabilize their structure. The
fact that very few proteins do form amyloid in vivo may be
explained as a result of billions of years of protein evolution.
This point of view predicts that, in general, proteins prone to
convert to the prion state are not likely to carry a specific
prion consensus sequence and are not likely to be identified
by sequence analysis.
Probably, the most significant achievements reported at the
conference related to prion structure, in both the sense of
spatial structure and the role of the primary structure.
Important questions for the future relate to the mechanisms
of prion propagation, including the role of chaperones and
possible curing mechanisms. The number and variety of
known prion-like phenomena grows, but only the future will
show the full picture of their occurrence and importance for
living organisms.
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